Comparative Pharmacology
Head-to-head clinical analysis: BUTALBITAL ACETAMINOPHEN AND CAFFEINE versus BUTAPAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALBITAL ACETAMINOPHEN AND CAFFEINE versus BUTAPAP.
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE vs BUTAPAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalbital is a barbiturate that acts as a nonselective central nervous system depressant, enhancing GABAergic transmission by binding to the GABA-A receptor and increasing chloride influx, leading to sedation and anxiolysis. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and providing analgesic and antipyretic effects. Caffeine is a methylxanthine that antagonizes adenosine receptors, promoting vasoconstriction and enhancing analgesic efficacy.
Butapap is a combination analgesic containing butalbital (barbiturate) and acetaminophen. Butalbital potentiates the analgesic effect of acetaminophen by increasing GABAergic inhibition in the central nervous system, while acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
1-2 capsules (50mg butalbital, 300mg acetaminophen, 40mg caffeine) orally every 4 hours as needed, not to exceed 6 doses per day.
Butalbital/acetaminophen/caffeine: 1-2 capsules (50 mg butalbital/325 mg acetaminophen/40 mg caffeine) orally every 4 hours as needed, not to exceed 6 capsules per day.
None Documented
None Documented
Butalbital: 35-50 hours (long-acting barbiturate, risk of accumulation with repeated dosing). Acetaminophen: 2-4 hours (normal hepatic function). Caffeine: 3-7 hours (metabolized by CYP1A2).
Terminal elimination half-life: 2–3 hours; prolongation may occur in hepatic impairment.
Butalbital: ~90% renal as unchanged drug and metabolites; Acetaminophen: ~85% renal as sulfate and glucuronide conjugates; Caffeine: ~1% renal unchanged, primarily hepatic metabolism. Biliary/fecal minimal (<5%).
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates): ~90%; biliary/fecal excretion: ~10%.
Category C
Category C
Barbiturate Combination
Barbiturate Combination